CUV.AU Clinuvel Pharmaceuticals Ltd
- Market cap
- AUD 365M
- P/E
- 10.8x
- P/B
- 1.34x
- ROE
- 12.4%
- Dividend yield
- 0.69%
- Fundamental score
- 3.8/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is CUV.AU undervalued?
Graham numberCUV.AU trades 20.0% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Clinuvel Pharmaceuticals Ltd fundamental analysis
18 of 22 checks passedROE 1/2
Moderate return on equity (12.4%), between 10% and 20%.
ROA 1/1
Return on assets (11.5%) is above the industry median (-51.4%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-5.3%) is not above the 5-year average (7.1% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-5.3%) is below the industry median (-5.3%).
Revenue Growth 1/2
Revenue grew 6.3% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (0.7%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 498.7x against interest expense, well covered.
PE vs Market 1/1
PE (10.8x) is below the market median (15.0x).
PE vs Industry 1/1
PE (10.8x) is below the industry median (16.3x).
PBV 1/1
Price to book (1.3x) is below the industry median (4.4x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 14.4, limit 22.5).
PEG 0/1
PEG on 5-year earnings growth is 1.53, above 1.
Dividend Yield 0/2
Dividend yield (0.7%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 2/2
Dividends paid without a cut of more than 10% for 10 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 7.4%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Clinuvel Pharmaceuticals Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimu…
Full company profileClinuvel Pharmaceuticals Ltd financial statements
Clinuvel Pharmaceuticals Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 16.8M | 25.5M | 31.0M | 32.6M | 48.0M | 65.7M | 78.3M | 88.2M | 95.0M | 94.0M |
| Gross Profit | 16.2M | 24.5M | 30.6M | 18.4M | 35.2M | 46.6M | 50.6M | 80.4M | 79.1M | 78.2M |
| Operating Income | 6.80M | 12.2M | 16.7M | 10.2M | 26.7M | 33.1M | 40.9M | 48.0M | 45.7M | 40.5M |
| EBITDA | 6.85M | 12.3M | 18.4M | 12.0M | 28.2M | 35.1M | 46.4M | 56.3M | 57.2M | 41.5M |
| Net Income | 7.18M | 13.2M | 18.1M | 16.6M | 24.7M | 20.9M | 30.6M | 35.6M | 36.2M | 33.9M |
| EPS | 0.14 | 0.27 | 0.37 | 0.33 | 0.48 | 0.40 | 0.59 | 0.70 | 0.72 | 0.68 |
| Balance Sheet | ||||||||||
| Total Assets | 28.6M | 42.9M | 62.3M | 81.5M | 109M | 145M | 195M | 231M | 272M | 296M |
| Total Liabilities | 3.16M | 3.49M | 5.17M | 9.48M | 9.83M | 19.3M | 29.9M | 28.1M | 30.9M | 23.3M |
| Shareholders' Equity | 25.4M | 39.4M | 57.2M | 72.1M | 98.7M | 126M | 165M | 203M | 241M | 273M |
| Cash & Short-term Investments | 23.8M | 36.2M | 54.3M | 66.7M | 82.7M | 122M | 157M | 184M | 224M | 252M |
| Total Debt | - | - | 433K | 1.32M | 1.30M | 1.26M | 1,000K | 880K | 529K | 1.94M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 9.92M | 11.7M | 18.5M | 14.2M | 19.3M | 39.9M | 36.9M | 37.1M | 41.1M | 36.9M |
| Capital Expenditure | 67.5K | 75.1K | 258K | 889K | 854K | 434K | 1.03M | 5.58M | 299K | 1.60M |
| Free Cash Flow | 9.85M | 11.6M | 18.2M | 13.3M | 18.4M | 39.4M | 35.9M | 31.5M | 40.8M | 35.3M |
| Ratios | ||||||||||
| ROE | 28.3% | 33.6% | 31.7% | 23.1% | 25.0% | 16.6% | 18.6% | 17.6% | 15.0% | 12.4% |
| ROA | 25.1% | 30.8% | 29.1% | 20.4% | 22.8% | 14.4% | 15.7% | 15.4% | 13.3% | 11.5% |
| Net Profit Margin | 42.8% | 51.9% | 58.4% | 51.1% | 51.5% | 31.8% | 39.1% | 40.4% | 38.1% | 36.1% |
| Debt to Equity | - | - | 0.01x | 0.02x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Clinuvel Pharmaceuticals Ltd dividends
- Dividend yield
- 0.69%
- Forward dividend
- 0.05 AUD
- Payout ratio
- 7.4%
- Ex-dividend date
- Sep 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | AUD 2.51M | 0.05 | 7.4% |
| 2025 | AUD 2.50M | 0.05 | 6.9% |
| 2024 | AUD 2.47M | 0.05 | 6.9% |
| 2023 | AUD 1.98M | 0.04 | 6.5% |
| 2022 | AUD 1.24M | 0.02 | 5.9% |
| 2021 | AUD 1.24M | 0.02 | 5.0% |
| 2020 | AUD 1.22M | 0.02 | 7.4% |
| 2019 | AUD 957K | 0.02 | 5.3% |
| 2018 | AUD 957K | 0.02 | 7.2% |
| 2017 | AUD 957K | 0.02 | 13.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Nov 12, 2010.
Who owns Clinuvel Pharmaceuticals Ltd
- Insiders 16.57%
- Institutions 12.98%
- Public & others 70.45%
- Shares outstanding 50.5M
- Free float 42.1M
Top funds holding CUV.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard International Stock Index-Total Intl Stock Indx | 648K | 1.31% | - | Oct 2020 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 247K | 0.50% | - | Dec 2020 |
| iShares Core MSCI EAFE ETF | 182K | 0.37% | - | Feb 2021 |
| iShares MSCI EAFE Small Cap ETF | 178K | 0.36% | - | Feb 2021 |
| College Retirement Equities Fund-Stock Account | 112K | 0.23% | - | Dec 2020 |
| DFA Asia Pacific Small Company Series | 108K | 0.22% | - | Jan 2021 |
| Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 95.6K | 0.19% | - | Oct 2020 |
| Bernstein Fund, Inc.-International Small Cap Portfolio | 87.5K | 0.18% | - | Dec 2020 |
| Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 53.6K | 0.11% | - | Nov 2020 |
| DFA International Core Equity Portfolio | 42.9K | 0.09% | - | Jan 2021 |
Clinuvel Pharmaceuticals Ltd company profile
- Company name
- Clinuvel Pharmaceuticals Ltd
- Ticker
- CUV.AU
- ISIN
- AU000000CUV3
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 535 Bourke Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9660 4900
- Website
- clinuvel.com
About Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Clinuvel Pharmaceuticals Ltd management
9- Dr. Philippe Jacques Wolgen M.B.A., M.D.CEO, MD & Director · born 1963
- Mr. Peter VaughanChief Financial Officer
- Mr. Lachlan HayChief Operations Officer
- Dr. Dennis J. Wright BPharm, M.Sc., Ph.D.Chief Scientific Officer
- Mr. Malcolm BullHead of Australian Operations & Investor Relations
- Dr. Azza HamilaHead of Quality Assurance & Drug Safety
- Ms. Claire Newstead-Sinclair C.A.Company Secretary
- Dr. Linda TengDirector of North American Operations
- Dr. Emilie RodenburgerDirector of Global Clinical Affairs